1. Home
  2. NVCR vs NABL Comparison

NVCR vs NABL Comparison

Compare NVCR & NABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • NABL
  • Stock Information
  • Founded
  • NVCR 2000
  • NABL 2000
  • Country
  • NVCR Switzerland
  • NABL United States
  • Employees
  • NVCR N/A
  • NABL N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • NABL Computer Software: Prepackaged Software
  • Sector
  • NVCR Health Care
  • NABL Technology
  • Exchange
  • NVCR Nasdaq
  • NABL Nasdaq
  • Market Cap
  • NVCR 1.4B
  • NABL 1.5B
  • IPO Year
  • NVCR 2015
  • NABL N/A
  • Fundamental
  • Price
  • NVCR $12.15
  • NABL $8.23
  • Analyst Decision
  • NVCR Buy
  • NABL Buy
  • Analyst Count
  • NVCR 7
  • NABL 4
  • Target Price
  • NVCR $28.79
  • NABL $9.31
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • NABL 768.9K
  • Earning Date
  • NVCR 10-29-2025
  • NABL 11-06-2025
  • Dividend Yield
  • NVCR N/A
  • NABL N/A
  • EPS Growth
  • NVCR N/A
  • NABL N/A
  • EPS
  • NVCR N/A
  • NABL 0.01
  • Revenue
  • NVCR $630,160,000.00
  • NABL $482,397,000.00
  • Revenue This Year
  • NVCR $6.68
  • NABL $9.54
  • Revenue Next Year
  • NVCR $7.01
  • NABL $8.71
  • P/E Ratio
  • NVCR N/A
  • NABL $542.40
  • Revenue Growth
  • NVCR 14.58
  • NABL 7.40
  • 52 Week Low
  • NVCR $10.87
  • NABL $6.07
  • 52 Week High
  • NVCR $34.13
  • NABL $13.12
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 46.57
  • NABL 55.38
  • Support Level
  • NVCR $11.98
  • NABL $8.10
  • Resistance Level
  • NVCR $12.83
  • NABL $8.45
  • Average True Range (ATR)
  • NVCR 0.56
  • NABL 0.23
  • MACD
  • NVCR 0.15
  • NABL 0.05
  • Stochastic Oscillator
  • NVCR 25.49
  • NABL 58.05

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About NABL N-able Inc.

N-able Inc is a provider of cloud-based software solutions for managed service providers (MSPs), enabling them to support digital transformation and growth for small and medium-sized enterprises. With a flexible technology platform and powerful integrations, N-able makes it easy for MSPs to monitor, manage, and protect their end-customer systems, data, and networks. The company's growing portfolio of management, security, automation, and data protection solutions is built for IT services management professionals. Geographically, the majority of revenue is from the United States. The company also has a presence in the United Kingdom and all other International regions.

Share on Social Networks: